

What is claimed is:

1. A complex of protein-protein interactions as defined in SEQ ID Nos. 2 and 4.
2. A complex of polynucleotides as defined in SEQ ID Nos. 1 and 3 encoding for the polypeptides.
3. A recombinant host cell expressing the interacting polypeptides as defined in Table 1.
4. A method for selecting a modulating compound comprising:
  - (a) cultivating a recombinant host cell with a modulating compound on a selective medium and a reporter gene the expression of which is toxic for said recombinant host cell wherein said recombinant host cell is transformed with two vectors:
    - (i) wherein said first vector comprises a polynucleotide of SEQ ID No. 1 encoding a first hybrid polypeptide and a DNA bonding domain;
    - (ii) wherein said second vector comprises a polynucleotide of SEQ ID No. 3 encoding a second hybrid polypeptide and an activating domain that activates said toxic reporter gene when the first and second hybrid polypeptides interact;
  - (b) selecting said modulating compound which inhibits the growth of said recombinant host cell.
5. A modulating compound obtained by the method of Claim 4.
6. A vector comprising the polynucleotide comprising the SEQ ID Nos. 1 or 3.
7. A fragment of a polypeptide comprising SEQ ID Nos. 2 and 4.
8. A variant of a polypeptide comprising SEQ ID Nos. 2 and 4.
9. A fragment of a polynucleotide comprising SEQ ID Nos. 1 and 3.
10. A variant of said polynucleotide comprising SEQ ID Nos. 1 and 3.
11. A recombinant host cell containing the vectors according to Claim 6.
12. A pharmaceutical composition comprising a modulating compound of Claim 5 and a pharmaceutically acceptable carrier.
13. A pharmaceutical composition comprising the recombinant host cells of Claim 11 and a pharmaceutically acceptable carrier.

14. A protein chip comprising the polypeptides of Claims 7 or 8.
15. A monoclonal antibody of the protein complex of Claim 1.

1002330-121804